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Introduction
Breast cancer is the most common cancer among women. 
Globally, 1.67 million women were diagnosed with breast 
cancer in 2012, contributing to more than 25% of female cancer 
incident cases.1 The incidence of breast cancer among Chinese 
women is increasing twice as fast as the global rate.2 In China, 
breast cancer is the most frequently diagnosed cancer and the 
fifth leading cause of cancer-related deaths.3
Breast cancer is a potentially curable disease if diagnosed 
and treated at an early stage. The Surveillance, Epidemiology, 
and End Results Programme reported that women diagnosed 
with breast cancer at an early stage (Stage I or II) have a better 
prognosis (5-year survival rate, 85–98%) than for advanced 
breast cancer (5-year survival rate for Stage III or IV, 30–70%).4 
The strong argument for earlier diagnosis with respect to pa-
tient outcome has resulted in the initiation of breast cancer 
screening programmes in many countries. The aims of such 
programmes are the early diagnosis and treatment of cancer 
patients to improve disease outcomes and to reduce mortality.5
Although population-based mammography has been 
widely adopted in high-income countries for more than 
30 years,6 it is less cost–effective in low- and middle-income 
countries.7 Studies in China,8–10 Ghana11 and the Islamic Re-
public of Iran12,13 have revealed that population-based mam-
mography is not economically attractive. However, a high-risk 
population-based breast cancer screening programme could 
contribute to a much higher detection rate14–16 and could 
therefore be good value for money in low- and middle-income 
countries.
Experts have recommended ultrasound as an adjunct to 
mammography among high-risk women.17–20 For patients with 
dense breasts, non-calcified breast cancers are more likely to be 
missed by mammography;21 ultrasound permits the detection 
of small, otherwise occult, breast cancer.22
In 2012, the Government of China launched a cancer 
screening programme in 14 cities to screen common can-
cers, including breast cancer. Our objective was to provide 
policy-makers with economic information regarding the 
cost–effectiveness of breast cancer screening for high-risk 
women. In this paper, we used a Markov model to compare the 
lifetime effects, costs and cost–effectiveness of breast cancer 




To measure the individual risk of breast cancer, health profes-
sionals invited women aged 40–69 years to health facilities 
and used paper-based questionnaires to collect information 
on individual breast cancer exposure. The health professionals 
then used the Harvard Cancer Index online tool, now called 
Your Disease Risk, to process the collected information.23,24 The 
tool calculates individual cancer scores, by giving risk scores to 
exposures, including family history, height, age of first period, 
age of first birth, number of births, age at menopause, use of 
oral contraceptives, estrogen replacement, Jewish heritage (i.e. 
higher prevalence of BRAC1/2 gene mutations) and exposure 
to ionizing radiation. A total of 198 097 women completed a 
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risk assessment questionnaire during 
2012–2013; 17 104 were identified as 
being at high risk of developing breast 
cancer.14
The programme working group 
estimated the population average score 
based on the prevalence of risk factors 
among the Chinese population, and 
adjusted according to China’s cancer epi-
demiology data over 20 years.14 The rela-
tive risk was obtained by comparing the 
individual risk score with the population 
average. Women with a relative risk of 
> 2 are defined as being at high risk. The 
programme screens high-risk women 
aged 40–44 years by ultrasound and the 
women with suspected results are further 
examined by mammography. Women 
with a suspicious mammography result 
are tested by biopsy for diagnostic con-
firmation. The programme screens high-
risk women aged 45–69 years by both 
mammography and ultrasound, and 
suspected results from either method 
are confirmed with biopsy.
For low-risk women, breast cancer 
is only diagnosed on presentation of 
symptoms. Breast cancer patients in the 
screening arm can be diagnosed while still 
asymptomatic, that is, at an earlier stage 
of the disease when prognosis is better.
Modelling strategy
Box 1 presents our model assumptions. 
We adapted a prior natural history Mar-
kov model8 using the TreeAge software 
(TreeAge software Inc. Williamstown, 
United States of America), to inform a 
long-term decision model. Our model 
predicted the lifetime costs and quality-
adjusted life years (QALYs) of screening 
and no screening for Chinese urban 
women with no previous history of 
breast cancer, from age 40 years to death. 
We used an annual screening frequency 
as the baseline, and we explored the sce-
narios of screening every 3 and 5 years.
Natural history
Fig. 2 illustrates the various health states 
and the potential transitions between 
them.8 Healthy women can transition 
to ductal carcinoma in situ or stage I 
cancer, or remain free of cancer. Women 
with ductal carcinoma in situ are at a 
higher risk of developing invasive breast 
cancer (relative risk: 2.02).4 Patients at 
stage I can progress to stage II, stage 
III and stage IV in turn. All women 
can die from causes other than breast 
cancer during disease progression, but 
only patients at stage IV can die from 
breast cancer. The state progression 
transition probabilities used in this 
analysis are from models described in 
the literature.8,25
We estimated the probability of 
symptoms in an unscreened population 
by calibrating the model as follows. In 
the non-screening arm, incident cases 
are only detected on presentation with 
symptoms; the distribution of incidence 
cases by stage is therefore a function of 
the probability of transitions and the 
probability of symptoms.26 We adjusted 
the probability of symptoms until the 
distribution of cases presented at each 
stage was similar to the distribution 
of reported incidence cases.3,27 Our 
estimates of transition probabilities are 
provided in Table 1.
We assumed that all suspected 
cases proceeded to biopsy and that all 
diagnosed cases received treatment at 
Fig. 1. Current risk-based breast cancer screening programme in urban China, launched 
in 2012
Women aged 40–69 years assessed with a cancer-risk questionnaire
Women with low risk not screened Women with high risk screened
Biopsy done in women with at least 
one suspicious result
Treatment for diagnosed women
Women presenting with symptoms diagnosed
Treatment for diagnosed women
Women 45–69 years 
screened with ultrasound 
and mammography
Women 40–44 years 
screened with ultrasound
Women with suspected 
results screened with 
mammography 
Box 1. Model assumptions for estimating cost–effectiveness ratios of risk-based breast 
cancer screening programme in urban China
Parameters
• For progression rates between disease stages and relative risk of invasive cancer in ductal 
carcinoma in situ, we obtained data from other countries and assumed the parameters 
were applicable to China. We also used disutility score of screening from United Kingdom 
of Great Britain and Northern Ireland in the baseline analysis. However, we explored the 
uncertainty in the sensitivity analyses.
• We assumed the risk of developing breast cancer among high-risk women was twice as 
much as the general population, based on the minimum threshold in Harvard Cancer Index 
(now called Your Disease Risk).
Model structure
• We assumed patients at stage I can progress to stage II, stage III and stage IV. All women 
can die from non-breast cancer causes during disease progression, but only patients at 
stage IV can die from breast cancer.
• We assumed all women with suspicious screening findings either with mammography or 
ultrasound proceeded to diagnostic biopsy. This follows the protocol of the Cancer Screening 
Programme in Urban China.
• In the base-case analysis, we assumed all breast cancer patients diagnosed by biopsy 
received treatment. However, because uptake of treatment is uncertain, we explored the 
scenario where only 70% of detected breast cancers received treatment.
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baseline. We also explored a scenario of 
only 70% treatment uptake.
Epidemiological and clinical data
We obtained the age-specific invasive 
breast cancer incidences from the 2012 
Chinese Cancer Registry Annual Re-
port.3 Since ductal carcinoma in situ 
incidence is not recorded locally, we 
estimated the proportion of ductal car-
cinoma in situ among all breast cancer 
incidence cases from a Chinese study 
of 3838 patients.28 We calculated age-
specific mortalities from other causes 
by subtracting age-specific breast cancer 
mortality rates35 from the corresponding 
age-specific all-cause mortality rates.36
Costs
Data describing the costs of question-
naire, screening (whether ultrasound 
followed by mammography if required 
or ultrasound plus mammography, de-
pending on age) and biopsy were avail-
able from the screening programme.32 
We also obtained the treatment costs by 
stage from the study by the programme 
working group;34 such treatment cost 
data were estimated from 2746 inva-
sive breast cancer patients from 37 
hospitals across 13 provinces in China, 
comprising direct medical costs, direct 
non-medical costs and indirect costs. 
We used the disposable income per 
capita of Chinese urban residents (22.5 
United States dollars (US$) per day)37 
and productivity loss days to calculate 
the indirect costs. The Chinese screen-
ing programme did not report treatment 
costs for women with ductal carcinoma 
in situ, so we estimated these costs from 
a study of 211 Sichuan Cancer Hospital 
patients.33 All costs are presented at 2014 
values. We used the purchasing power 
parity conversion factor to convert cost 
values to US$, with US$ 1 equal to 3.51 
Chinese yuan.38
Effectiveness of screening
We used the sensitivity (probability 
of positive diagnosis if diseased) and 
specificity (probability of negative 
diagnosis if not diseased) values from 
an earlier study29 that enrolled 3062 
Chinese women (average age, 45 years) 
at risk of breast cancer. 11 screening 
modalities were compared, which are 
different combinations of clinical breast 
examination, mammography and ul-
trasound. We varied the estimates in 
the sensitivity analyses in case of any 
variation in diagnostic performance due 
to the age of the screened population.
QALYs
QALY is a measurement that reflects 
both length of life and health-related 
quality of life. It is calculated as the prod-
uct of the utility score of a particular 
state of health, defined as a dimension-
less number between 1 (perfect health) 
and 0 (death), and the number of years 
lived. We identified the utility scores for 
patients at stage I, II, III and IV from 
a cross-sectional survey conducted as 
part of the screening programme,30 in 
which breast cancer patients across 13 
Chinese provinces completed EuroQol 
five-dimensional questionnaires.
False-positive results could be ar-
gued to undermine quality of life due 
to psychological distress incurred;39 a 
systematic review estimated a utility 
decrement (disutility) of 11–34% for 
false-positive results.31 We estimated a 
loss of 25% at baseline40 and explored the 
uncertainty in the sensitivity analysis.
Analysis
In agreement with the China Guidelines 
for Pharmacoeconomic Evaluations,41 
we conducted the analysis from a so-
cietal perspective. In agreement with 
these guidelines,41 we discounted future 
costs and future benefits at 3%. We es-
timated the lifetime costs of screening 
and its effects in terms of QALY. We 
calculated the incremental cost–effec-
tiveness ratios, defined as the difference 
in cost divided by the change in QALY. 
The willingness-to-pay threshold was 
estimated to be three times the gross 
domestic product (GDP) per capita in 
China in 2014 (US$ 7683).42 An incre-
mental cost–effectiveness ratio of less 
than US$ 23 050/QALY41 is therefore 
an indication that the risk-based breast 
cancer screening for urban Chinese 
women aged 40–69 years, compared 
with no screening, is cost–effective.
To explore the effect of parameter 
uncertainty, we conducted one-way and 
probabilistic sensitivity analyses. In the 
one-way sensitivity analysis, we used the 
minimum and maximum estimates for 
effectiveness of screening, utility scores 
and costs. We varied each parameter in-
dividually to assess its impact on overall 
results. In the probabilistic sensitivity 
analysis, we varied all variables simulta-
neously to further explore model uncer-
tainty. The input variables were specified 
as distributions: costs have a gamma 
distribution; QALY values follow a log-
normal distribution; and sensitivity and 
specificity of screening follow a beta dis-
tribution as suggested in the literature.43 
By varying input parameters over their 
respective distributions, we obtained 
1000 estimates of incremental costs and 
incremental effects. We then plotted the 
cost–effectiveness acceptability curves 
to show the proportion of simulations 
for which the intervention was cost–ef-
fective at different willingness-to-pay 
thresholds.
Other scenarios explored included: 
(i) the impact of screening every 3 years 
or every 5 years, compared with no 
screening; (ii) screening every year, but 
only 70% of the detected cases having 
Fig. 2. Natural history model for breast cancer progression, China
















Notes: The box represents the process of disease progression. We adapted the model from Wong et al.8,25 and Tsokos & Oğuztöreli.25
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Table 1. Parameter values for modelling cost–effectiveness of risk-based breast cancer screening programme launched in 2012 in urban 
China
Variables Baseline Minimum Maximum Distribution Reference/source
Disease state progression transition probabilities
Age-specific incidence, years
  40–44 0.0006100 – – – Chinese Cancer Registry Annual 
Report3 
  45–49 0.0010056 – – – Chinese Cancer Registry Annual 
Report3 
  50–54 0.0011650 – – – Chinese Cancer Registry Annual 
Report3 
  55–59 0.0011179 – – – Chinese Cancer Registry Annual 
Report3 
  60–64 0.0010458 – – – Chinese Cancer Registry Annual 
Report3 
  65–69 0.0009782 – – – Chinese Cancer Registry Annual 
Report3 
  70–74 0.0009912 – – – Chinese Cancer Registry Annual 
Report3 
  75–79 0.0009067 – – – Chinese Cancer Registry Annual 
Report3 
  80–84 0.0007803 – – – Chinese Cancer Registry Annual 
Report3 
  ≥ 85 0.0006430 – – – Chinese Cancer Registry Annual 
Report3 
Ratio of DCIS incidence 
to invasive breast cancer 
incidence
0.12 – – – Lu et al.28
RR of invasive cancer from DICS 2.02 – – – SEER Program4
Progression rate
  Stage I–Stage II 0.06 – – – Tsokos & Oğuztöreli25 
  Stage II–Stage III 0.11 – – – Tsokos & Oğuztöreli25 
  Stage III–Stage IV 0.15 – – – Tsokos & Oğuztöreli25 
  Stage IV–death 0.23 – – – Wong et al.8
Stage-specific probability of symptoms
  Stage I 0.004 – – – Model calibration
  Stage II 0.014 – – – Model calibration
  Stage III 0.380 – – – Model calibration
  Stage IV 0.980 – – – Model calibration
Annual fatality rate after treatment
  Stage I 0.006 – – – Ginsberg et al.27
  Stage II 0.042 – – – Ginsberg et al.27
  Stage III 0.093 – – – Ginsberg et al.27
  Stage IV 0.275 – – – Ginsberg et al.27
Effectiveness of screening
Ultrasound followed by mammography if requireda
  Sensitivity 0.848 0.681 0.949 Beta Huang et al.29
  Specificity 0.994 0.990 0.996 Beta Huang et al.29
Ultrasound and mammography
  Sensitivity 0.939 0.798 0.993 Beta Huang et al.29
  Specificity 0.980 0.975 0.985 Beta Huang et al.29
Utility scores
  Stage I 0.79 0.77 0.80 Log-normal Shi et al.30
  Stage II 0.79 0.78 0.80 Log-normal Shi et al.30
  Stage III 0.77 0.76 0.79 Log-normal Shi et al.30
  Stage IV 0.69 0.65 0.72 Log-normal Shi et al.30
Disutility from false-positive 0.25 0.11 0.34 Log-normal Peasgood et al.31
(continues. . .)
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access to breast cancer treatment; and 
(iii) screening women aged 45–69 years 
every 1, 3 and 5 years via mammogra-
phy and ultrasound, compared with 
mammography alone (maintaining the 
original screening strategy for women 
aged 40–44 years).
Results
Our model estimated 43 incident cases 
of breast cancer per 1000 women over 
a lifetime; 21 were detected via screen-
ing and 22 on presentation with symp-
toms. Table 2 reports the discounted 
lifetime costs, QALYs and incremental 
cost–effectiveness ratios. Overall, the 
risk-based breast cancer screening 
yielded higher QALYs compared with 
no screening (23.0129 QALYs versus 
22.9843 QALYs), but was more expen-
sive than no screening (US$ 335.43 ver-
sus US$ 99.68). The baseline discounted 
incremental cost–effectiveness ratio was 
US$ 8253/QALY, well below the thresh-
old of US$ 23 050/QALY, indicating that 
the risk-based breast cancer screening 
programme is cost–effective.
The one-way sensitivity analysis 
(Fig. 3) indicates that the costs, utility 
scores and effectiveness of screening 
have little individual influence on the 
cost–effectiveness of the programme. 
We found the incremental cost–ef-
fectiveness ratios to be lower than the 
threshold at both the upper and lower 
limits of these variables. The results 
of the probabilistic sensitivity analysis 
(Fig. 4) show that, at the threshold of 
US$ 23 050/QALY, nearly 100% of the 
simulations indicate that the risk-based 
breast cancer screening programme 
is cost–effective compared with no 
screening.
In the scenario analysis (Table 2), 
screening every 3 years and every 
5 years achieves an incremental cost–ef-
fectiveness ratio of US$ 6671/QALY 
and US$ 6917/QALY, respectively. 
A scenario of annual screening, but 
where only 70% of detected cases are 
treated, yields a higher incremental 
cost–effectiveness ratio of US$ 11 223/
QALY, which is still lower than the 
threshold. We also found the scenario 
of both mammography and ultrasound 
for women aged 45–69 years, compared 
with mammography alone, to be cost–ef-
fective. However, in the probabilistic 
sensitivity analysis, the confidence in-
tervals of the incremental cost–effective-
ness ratios are very wide: an indication 
of considerable uncertainty.
Discussion
The results indicate that compared with 
no screening, the risk-based breast can-
cer screening programme is cost–effec-
tive. The results prove to be robust in the 
sensitivity analyses when we varied the 
estimates for effectiveness of screening, 
utility scores and costs.
Our finding that high-risk popula-
tion-based breast screening is cost–ef-
fective has implications for breast 
cancer control in other low- and middle-
income countries. Previous studies 
have reported that population-based 
mammography screening is not eco-
nomically attractive in countries, such 
as the Islamic Republic of Iran and 
Ghana, with incremental cost–effective-
ness ratios of US$ 389 184/QALY12 and 
US$ 12 908/QALY,11 respectively. The 
Chinese screening programme is more 
likely to be cost–effective than other 
general population-based screening pro-
grammes, since the detection rate in the 
Chinese programme is higher (16%)14 
than in general screening programmes 
(e.g. 3% in the United States of America 
and 6% in New Zealand).15,16 This find-
ing is consistent with the study compar-
ing risk-based breast cancer screening 
strategies with general programmes, 
reporting that risk-based strategies 
result in greater health benefits for a 
given cost.44
For high-risk women aged 45–
69 years, our scenario analysis shows 
that the benefits of ultrasound in ad-
dition to mammography are consider-
ably uncertain. The wide confidence 
intervals, indicating uncertainty in the 
incremental cost–effectiveness ratios, 
do not appear to justify the increased 
costs. A potential alternative to the cur-
rent screening strategy could therefore 
be mammography screening alone for 
high-risk women aged 45–69 years, 
instead of both ultrasound and mam-
mography.
Screening every 3 years is the most 
cost–effective frequency among alterna-
tives. Compared with screening every 
year, screening every 3 years decreases 
the total costs significantly, but does 
not change the effects significantly. 
The results vindicate the 3-year screen-
ing interval for breast cancer in some 
countries, such as the United Kingdom 
of Great Britain and Northern Ireland.5
Our study explored the impact 
of access to treatment on the overall 
results, suggesting that the screening 
Variables Baseline Minimum Maximum Distribution Reference/source
Costs, US$  
Questionnaire 1.6 1.1 2.1 Gamma Cancer Screening Programme 
in Urban China32
Screening 85.5 59.8 111.1 Gamma Cancer Screening Programme 
in Urban China32
Biopsy 45.6 31.0 59.3 Gamma Cancer Screening Programme 
in Urban China32
Treatment costs
DCIS 2435 1705 3166 Gamma Li et al.33
  Stage I 10 067 7047 13 087 Gamma Liao et al.34
  Stage II 11 068 7748 14 388 Gamma Liao et al.34
  Stage III 12 867 9007 16 727 Gamma Liao et al.34
  Stage IV 17 766 12 436 23 096 Gamma Liao et al.34
DCIS: ductal carcinoma in situ; US$: United States dollars.
a  For women aged 40–44 years.
b  For women aged 45–69 years.
(. . .continued)
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programme is less cost–effective if not 
all detected cases go on to receive treat-
ment. In China, patients need to pay on 
average 34% of total medical costs;45 this 
can limit access to medical treatment for 
some women who have been diagnosed 
with breast cancer. Some women may 
also decide not to seek medical treat-
ment if they are not experiencing any 
pain or do not feel ill;46 such delays in the 
onset of treatment can however lead to a 
poorer prognosis,46 reducing the cost–ef-
fectiveness of a screening programme.
As with the previous models,8 we 
adopted the Markov approach in our 
Table 2. Modelled cost–effectiveness ratios of risk-based breast cancer screening programme in urban China, 2014
Comparators Lifetime costs 
per case (US$)






No screening 99.68 22.9843 – – –
Annual screening 335.43 23.0129 235.76 0.0286 8 253 (6 170 to 11 483)
Screening programme variations versus no screening
Screening every 3 years 184.67 22.9971 84.99 0.0127 6 671 (5 019 to 9 048)
Screening every 5 years 152.09 22.9919 52.41 0.0076 6 917 (5 157 to 9 416)
Annual screening, but only 70% of 
detected cases treated
324.17 23.0043 224.49 0.0200 11 223 (8 137 to 17 127)
Mammography only versus mammography and ultrasoundb
Annual screening 306.41 23.0115 −29.02 −0.0014 21 246 (−172 049 to 168 866)
Screening every 3 years 172.94 22.9960 −11.73 −0.0011 11 000 (−73 330 to 99 983)
Screening every 5 years 145.37 22.9912 −6.72 −0.0007 9 366 (−114 804 to 98 149)
CI: confidence interval; ICER: incremental cost–effectiveness ratio; RR: relative risk; QALY: quality-adjusted life year; US$ United States dollars.
a  Discounted at 3%.
b  For women aged 45–69 years. Screening regime for women aged 40–44 years remains unchanged.
Note: Some inconsistency arise in some value due to rounding.
Fig. 3. One-way sensitivity analysis of modelled cost–effectiveness of risk-based breast cancer screening programme, urban China, 2014
Screening costs
Disutility from false-positive
Cost at stage I
Sensitivity of ultrasound and mammography
Utility at stage I
Specificity of ultrasound and mammography
Questionnaire cost
Cost at stage III
Cost at stage II
Cost at stage IV
Utility at  stage III
Specificity of ultrasound followed by mammography
Sensitivity of ultrasound followed by mammography
Utility at stage II
Cost at stage 0
Utility at stage IV
Biopsy cost
ICER (US$/QALY)
6500 7000 7500 8000 8500 9000 9500 10 000
ICER: incremental cost–effectiveness ratio; QALY: quality-adjusted life year; US$: United States dollars.
Notes: The width of the bars represents the range of ICER when each parameter was varied individually. The vertical dashed line represents incremental cost–
effectiveness ratio of US$ 8253/QALY.
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modelling. While costs and quality of 
life are provided in the publications by 
the Chinese screening programme,30,32,34 
no long-term follow-up data are avail-
able. We therefore used a mathematical 
model from age 40 years to death to 
reflect the differences in costs and ef-
fects. We also adopted a prior natural 
history model, meaning that women free 
of breast cancer first transition to ductal 
carcinoma in situ or stage I, followed 
by the remaining stages in sequence; in 
contrast, another study47 used a model 
in which it is possible to progress from 
being free of breast cancer to stage IV. 
In addition, we calibrated our model to 
estimate the probability of symptoms by 
cancer stage, using the distribution of 
incidence cases reported in the Chinese 
Cancer Registry Annual Report 20123 in 
an unscreened population.
Further, we incorporated the decre-
ments in health-related quality of life 
from false-positive screening results 
into our model. In this analysis, we used 
a loss of 25% at baseline and explored 
the uncertainty (11–34%). However, the 
utility loss from false–positive results39 
remains controversial. Although some 
argue that pathologically elevated levels 
of distress and anxiety are not appar-
ent,48 the relatively small number of 
studies means that the long-term effects 
of false-positive breast cancer screening 
are still unknown.48 In this analysis we 
used estimates from studies based in 
the United Kingdom of Great Britain 
and Northern Ireland,31,40 which might 
bias the cost–effectiveness results of the 
Chinese screening programme. How-
ever, we explored the uncertainty and 
the results proved to be robust through 
the sensitivity analyses.
Limitations of our study also in-
clude the assumption of high-risk wom-
en having a cancer risk index twice that 
of other women;23 the real relative risk 
among high-risk women in urban China 
is still unknown. Further, the costs of 
questionnaires and clinical screening 
in this study are derived from the cost 
accounting of the screening programme; 
other implementation costs such as the 
identification of eligible women, the ad-
ministration of risk questionnaires and 
other ancillary costs were not included. 
This may lead to an underestimation of 
costs and subsequently the cost–effec-
tiveness. For progression rates between 
stages and the relative risk of invasive 
cancer from ductal carcinoma in situ, 
we used data from other countries and 
assumed the parameters were applicable 
to China. These factors require careful 
consideration and further research is 
required to reduce uncertainty.
We used three times the Chinese 
gross domestic product (GDP) per 
capita as the willingness-to-pay thresh-
old in our cost–effectiveness analysis. 
Although GDP-based thresholds are 
commonly cited,41 they have been cri-
tized.49 Even if estimated accurately, 
GDP-based cost–effectiveness ratios, 
or other estimates of willingness to pay, 
do not provide information on afford-
ability, budget impact or the feasibly of 
implementation. Although cost–effec-
tiveness ratios are informative in assess-
ing value for money, willingness-to-pay 
thresholds should therefore not be used 
alone as a decisions rule for priority set-
ting. Local policy context must also be 
considered.49
In conclusion, our analysis provides 
economic evidence for the cost–effec-
tiveness of risk-based breast cancer 
screening in urban China. ■
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Fig. 4. Probabilistic sensitivity analysis of modelled cost–effectiveness of risk-based 
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QALY: quality-adjusted life year; US$: United States dollars.
Note: The vertical dashed line represents incremental cost–effectiveness ratio of US$ 8253/QALY.
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صخلم
ينصلا ،رطاخلما لىع مئاقلا يدثلا ناطسر صحف جمانبرل ةفلكتلا ةيلاعف
 ناطسر  صحف  جمانبرل  ةفلكتلا  ةيلاعفل  جذومن  عضو  ضرغلا
 في هقلاطإ مت يذلاو ،ةيضرلحا ينصلا في رطاخلما لىع مئاقلا يدثلا
.صحف ءارجإ مدعب ةنراقم ،2012 ماع
 راثلآاو فيلاكتلا ريدقتل فوكرام جذومن ريوطتب انمق دقل ةقيرطلا
 ،)QALYs(  ةدولجا  ةلدعم  رمعلا  تاونس  ةبسنلاب  ،ةايلحا  ىدم
 في  يربك  رطلخ  تاضرعلما  ءاسنلل  يدثلا  ناطسر  صحف  جمانبرل
 دمتعت- تانايب انجهتنا وأ انطبنتسا دقل .ًاماع 69 لىإ 40 نم نس
 خيراتلا  مدقت ضاترفاب  ،ثودلحاو لاقتنلاا ةيلماتحلا -نسلا لىع
 انلصح  دقل  .ىرخأ  تاسارد  نم  ،ناطسرلا  لحارم  ينب  يعيبطلا
 2014  ماعلا  لاوط  شرابلما  يرغو  شرابلما  جلاعلا  فيلاكت  لىع
 37 في يدثلا ناطسر تاضيرلم تاحوسم نم يكيرملأا رلاودلاب
 قفارملل تماييقت جاتنتساب انمق ،QALY باسلح .اًينيص ىفشتسم
 بسن مييقتب انمق .ضىرملل تاعاطقلا ةددعتم تاحوسم للاخ نم
 ةنراقملل كلذو ،تاهويرانيسلا فلتخلم فيلاكتلا ةيلاعفل ةديازتم
.عفدلل دادعتسلاا ةبتع عم
 ةديازتم ةبسن نع يونسلا صحفلل سياسلأا انجذومن رفسأ جئاتنلا
 لقأ يهو ،QALY/يكيرمأ رلاود 8253 اهردق ةفلكتلا ةيلاعفل
/يكيرمأ رلاود 23050 اهتميق ةغلابلا عفدلل دادعتسلاا ةبتع نم
 ةيلماتحلااو  هاتجلاا  ةيداحأ  ةيساسلحا  تلايلتح  ترهظأ  .QALY
 نإف  ،ةفلتخلما  تاهويرانيسلا  فاشكتسا  عمو  .ةيوق  جئاتنلا  نأ
 ،ةفلكتلا ثيح نم ةيلاعف رثكلأا وه نوكي تاونس 3 لك صحفلا
/اًيكيرمأ  اًرلاود  6671  غلبت  ةفلكتلا  ةيلاعفل  ةديازتم  ةبسن  عم
 تياوللا  ءاسنلا  لك مقت لم اذإ  صحفلا ةفلكت ةيلاعف لقت .QALY
 ةيداصتقلاا ةدئافلا  نإف ،اًيرخأو .جلاعلل يعسلاب  نهصيخشت متي
 اًماع  69و  45  ينب  نهرماعأ  حواترـت  تياوللا  ءاسنلا  صحفل
 يعاعشلا  ريوصتلاو  ةيتوصلا  قوف  تاجولما  نم  لك  مادختساب
.ةدكؤم يرغ ،هدحو يدثلل يعاعشلا صحفلاب ًةنراقم ،يدثلل
 ةيلاع ةيناكسلا تاعمجتلا في يدثلا  ناطسر صحف نإ جاتنتسلاا




目的 为 2012 年启动的中国城市基于风险的乳腺癌筛
查项目建模进行成本效果分析，与不筛查的情况进行
比较。










益比为 8253 美元 /QALY，低于 23050 美元 /QALY 的
意愿支付最低阈值。单因素和概率敏感性分析表明结
果可靠。在探索不同情景时，每三年进行一次筛查最
具成本效果，增量成本效果比为 6671 美元 /QALY。
如果并非所有被诊断的女性都寻求治疗，筛查的成本
效果会降低。最后，与单独使用乳腺钼靶 X 线摄像比





Rapport coût-efficacité du programme de dépistage du cancer du sein fondé sur les risques en Chine
Objectif Modéliser le rapport coût-efficacité d’un programme de 
dépistage du cancer du sein fondé sur les risques en Chine urbaine, 
lancé en 2012, comparé à l’absence de dépistage.
Méthodes Nous avons élaboré un modèle de Markov pour estimer 
le coût et les effets portant sur la vie entière, au regard des années de 
vie pondérées par la qualité (QALY), d’un programme de dépistage du 
cancer du sein chez les femmes à haut risque âgées de 40 à 69 ans. 
Nous avons tiré ou adopté des données sur l’incidence selon l’âge et 
la probabilité de transition, dans l’hypothèse d’une évolution naturelle 
entre les phases du cancer, à partir d’autres études. Nous avons obtenu 
les coûts directs et indirects de traitement au cours d’une vie en dollars 
des États-Unis de 2014 ($US) à partir d’enquêtes menées auprès 
de patientes atteintes du cancer du sein dans 37 hôpitaux chinois. 
Pour calculer les QALY, nous avons déduit des scores d’utilité à partir 
d’enquêtes transversales auprès de patientes. Nous avons évalué le 
rapport coût-efficacité différentiel selon différents scénarios pour établir 
une comparaison avec un seuil de consentement à payer.
Résultats Notre modèle de référence de dépistage annuel a donné un 
rapport coût-efficacité différentiel de 8253 $US/QALY, soit moins que le 
seuil de consentement à payer de 23 050 $US/QALY. Les analyses à un 
seul critère de classification et de sensibilité probabiliste ont démontré 
que les résultats sont fiables. L’examen de différents scénarios a révélé 
que le dépistage tous les 3 ans présente le meilleur rapport coût-
efficacité, avec un rapport coût-efficacité différentiel de 6671 $US/QALY. 
Le rapport coût-efficacité du dépistage est réduit si toutes les femmes 
diagnostiquées ne se font pas soigner. Enfin, l’avantage économique 
lié au dépistage des femmes âgées de 45 à 69 ans par échographie 
et mammographie, comparé à un dépistage par mammographie 
uniquement, est incertain.
Conclusion Le dépistage du cancer du sein dans les populations à haut 
risque présente un bon rapport coût-efficacité par rapport à l’absence 
de dépistage. 
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Резюме
Экономическая эффективность программы скринингового обследования рака молочной железы на 
основе оценки риска, Китай
Цель Смоделировать экономическую эффективность программы 
скринингового обследования рака молочной железы на основе 
оценки риска в городах Китая, которая была запущена в 2012 году, 
при сравнении с отсутствием скрининга.
Методы Авторы разработали марковскую модель для оценки 
затрат на медицинское обслуживание в течение жизни и 
результатов (с точки зрения количества лет жизни с поправкой 
на ее качество (QALY)) внедрения программы скринингового 
обследования рака молочной железы для женщин с высоким 
риском в возрасте 40–69 лет. Авторы вывели самостоятельно или 
позаимствовали данные о зависимости частоты возникновения 
рака от возраста и о вероятности перехода, основываясь на 
естественной истории прогрессирования между стадиями 
рака по данным других исследований. В ходе обследований 
пациентов с раком молочной железы в 37 китайских больницах 
были получены данные о прямых и косвенных затратах на 
медицинское обслуживание в течение жизни в долларах 
США (долл. США) по курсу 2014 года. Чтобы вычислить показатель 
QALY, авторы получили индексы оценки общего состояния 
здоровья из перекрестного обследования пациентов. Была 
проведена оценка инкрементных коэффициентов эффективности 
затрат для различных сценариев для сравнения с порогом 
платежеспособности.
Результаты Созданная авторами базовая модель ежегодного 
скрининга привела к увеличению коэффициента эффективности 
затрат в размере 8253 долл. США/QALY, что ниже порога 
платежеспособности в размере 23 050 долл. США/QALY. 
Односторонний и вероятностный анализ чувствительности 
показал, что результаты являются надежными. Исходя из 
результатов исследования различных сценариев, проведение 
скринингового обследования через каждые 3 года является 
наиболее рентабельным с инкрементным коэффициентом 
эффективности затрат в размере 6671 долл. США/QALY. 
Экономическая эффективность скринингового обследования 
снижается, если не все прошедшие диагностику женщины 
обращаются за лечением. Наконец, экономическая выгодность 
скринингового обследования женщин в возрасте 45–69 лет с 
использованием и ультразвука и маммографии по сравнению с 
результатами при использовании только маммографии является 
неопределенной.
Вывод Скрининговое обследование рака молочной железы 
среди женщин с высоким уровнем риска является экономически 
эффективным по сравнению с результатами при отсутствии 
скрининга. 
Resumen
Rentabilidad del programa de detección del cáncer de mama basado en el riesgo en China
Objetivo Demostrar la rentabilidad de un programa de detección del 
cáncer de mama basado en el riesgo en las zonas urbanas de China, 
iniciado en 2012, en comparación con la ausencia de detección.
Métodos Se desarrolló un modelo Markov para estimar los costes y 
efectos durante el ciclo vital, en términos de años de vida ajustados 
por calidad de vida (AVAC), de un programa de detección del cáncer 
de mama para mujeres con alto riesgo de entre 40 y 69 años de edad. 
Se obtuvieron o adoptaron datos de la probabilidad de incidencia y 
transición específicos por edad, sobre la hipótesis de una progresión de 
la historia natural entre los estadios del cáncer, a partir de otros estudios. 
Se obtuvieron los costes directos e indirectos del tratamiento vitalicio en 
dólares estadounidenses (USD) en 2014 a partir de encuestas a pacientes 
con cáncer de mama en 37 hospitales de China. Para calcular los AVAC, 
se derivaron las puntuaciones de los servicios públicos de las encuestas 
transversales a los pacientes. Se evaluaron las relaciones de rentabilidad 
incrementales para diversos escenarios en comparación con un umbral 
de la disposición a pagar.
Conclusión La detección del cáncer de mama basada en la población 
de alto riesgo es rentable en comparación con la ausencia de detección.
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